Some NMS have been evaluated in a limited number of asymptomatic subjects carrying the LRRK2 G2019S mutation [6], [31], [34] and hyposmia, depression and constipation have been found to occur in some non-manifesting carriers [31], [34], although some of these premotor features were found to be no more frequent in non-manifesting carriers than in non-carriers. Here, LRRK2 is linked to depressive symptom measurement.